Metabolic Diseases Drug Discovery World Summit.
This year's Metabolic Diseases Drug Discovery World Summit, consisting of a gathering of mostly researchers from pharmaceutical and biotech industry, was held in picturesque San Diego. The diverse programme covered recent advances in drug discovery and development for the treatment of type II diabetes, metabolic syndrome and obesity. The ranges of topics included basic physiology, therapeutic target identification/validation, lead development/optimisation, profiling of development candidates and update on clinical trials. This report will attempt to highlight some of the important developments presented at this symposium.
Liu
Gang
G
Metabolic Disease Research, R4MC, AP10, 100 Abbott Park Road, Abbott Park, IL 60064-6098, USA. gang.liu@abbott.com
D000818:Animals; D002626:Chemistry, Pharmaceutical; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism; D004195:Disease Models, Animal; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008659:Metabolic Diseases / Q000188:drug therapy* / Q000378:metabolism; D009765:Obesity / Q000188:drug therapy / Q000378:metabolism; D013329:Structure-Activity Relationship
D015507:Drugs, Investigational